Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLR Allarity Therapeutics	$0.93 -2.3%	$0.97	$0.61 ▼ $20.44	$13.99M	-0.14	1.10 million shs	589,724 shs
OTIC Otonomy	$0.01	$0.06	$0.01 ▼ $2.54	$582K	1.54	937,525 shs	N/A
SXTC China SXT Pharmaceuticals	$1.52 +0.7%	$2.10	$0.95 ▼ $11.92	$23.90M	1.24	1.14 million shs	65,135 shs
TCDAQ Tricida		$0.01	$0.01 ▼ $13.85	N/A	N/A	N/A	N/A

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLR Allarity Therapeutics	-2.33%	-14.08%	-13.28%	+14.27%	-94.62%
OTIC Otonomy	0.00%	0.00%	0.00%	0.00%	0.00%
SXTC China SXT Pharmaceuticals	+0.66%	-8.43%	-37.45%	-66.22%	-82.08%
TCDAQ Tricida	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLR Allarity Therapeutics	0.5426 of 5 stars	0.0	4.0	0.0	0.0	1.6	0.0	0.6
OTIC Otonomy	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	1.4623 of 5 stars	0.0	5.0	0.0	0.0	4.1	0.0	0.6
TCDAQ Tricida	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLR Allarity Therapeutics	N/A	N/A	N/A
OTIC Otonomy	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A
TCDAQ Tricida	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLR Allarity Therapeutics	N/A	N/A	N/A	N/A	($559.39) per share	N/A
OTIC Otonomy	$130K	4.48	N/A	N/A	$0.97 per share	0.01
SXTC China SXT Pharmaceuticals	$1.82M	13.23	N/A	N/A	$30.46 per share	0.05
TCDAQ Tricida	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLR Allarity Therapeutics	-$11.90M	N/A	0.00	N/A	N/A	N/A	-369.67%	-100.06%	8/4/2025 (Estimated)
OTIC Otonomy	-$51.18M	-$0.77	N/A	∞	N/A	N/A	-137.86%	-68.50%	N/A
SXTC China SXT Pharmaceuticals	-$3.10M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
TCDAQ Tricida	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest OTIC, SXTC, TCDAQ, and ALLR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/13/2025	Q1 2025	ALLR Allarity Therapeutics	-$8.10	-$0.25	+$7.85	-$0.25	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLR Allarity Therapeutics	N/A	N/A	N/A	N/A	N/A
OTIC Otonomy	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TCDAQ Tricida	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLR Allarity Therapeutics	N/A	2.75	2.75
OTIC Otonomy	N/A	1.74	1.74
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A
TCDAQ Tricida	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLR Allarity Therapeutics	11.53%
OTIC Otonomy	41.23%
SXTC China SXT Pharmaceuticals	5.02%
TCDAQ Tricida	N/A

Insider Ownership

Company	Insider Ownership
ALLR Allarity Therapeutics	0.08%
OTIC Otonomy	1.09%
SXTC China SXT Pharmaceuticals	3.95%
TCDAQ Tricida	35.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLR Allarity Therapeutics	10	15.08 million	4.43 million	Not Optionable
OTIC Otonomy	51	68.53 million	67.78 million	Optionable
SXTC China SXT Pharmaceuticals	90	15.83 million	3.90 million	Not Optionable
TCDAQ Tricida	N/A	N/A	N/A	Optionable

OTIC, SXTC, TCDAQ, and ALLR Headlines

Recent News About These Companies

Chronic Kidney Disease News

December 2, 2023 | medscape.com

Brian C. Murray

November 13, 2023 | uwyo.edu

BAF Viet Nam Agriculture JSC (BAF)

July 14, 2023 | investing.com

Jiangxi JDL Environmental Protection Co Ltd (688057)

July 11, 2023 | investing.com

Multifaceted Interactions of Bacterial Toxins With the Gastrointestinal Mucosa

July 10, 2023 | medscape.com

RattanIndia Power Ltd (RTNP)

June 21, 2023 | investing.com

Tofas Turk Otomobil Fabrikasi AS (TOASO)

May 19, 2023 | investing.com

Mag Silver (NYSEMKT: MAG)

May 18, 2023 | fool.com

Tricida, Inc. (TCDAQ)

March 29, 2023 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
By Leo Miller | May 27, 2025
View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
NVIDIA-Backed CoreWeave Jumps 28%: Is It The Next Great AI Buy?
By Leo Miller | May 20, 2025
View NVIDIA-Backed CoreWeave Jumps 28%: Is It The Next Great AI Buy?
NVIDIA’s AI Robot Leap: 2 Stocks Set to Ride the Wave
By Nathan Reiff | May 23, 2025
View NVIDIA’s AI Robot Leap: 2 Stocks Set to Ride the Wave
Symbotic Gets Big Earnings Lift: Is the Stock Investable Again?
By Leo Miller | May 16, 2025
View Symbotic Gets Big Earnings Lift: Is the Stock Investable Again?

OTIC, SXTC, TCDAQ, and ALLR Company Descriptions

Allarity Therapeutics NASDAQ:ALLR

$0.93 -0.02 (-2.33%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$0.91 -0.02 (-1.93%)

As of 05/28/2025 07:59 PM Eastern

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Otonomy NASDAQ:OTIC

Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.

China SXT Pharmaceuticals NASDAQ:SXTC

$1.52 +0.01 (+0.66%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$1.48 -0.04 (-2.96%)

As of 05/28/2025 07:55 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

Tricida NASDAQ:TCDAQ

Tricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker on May 22, 2013 and is headquartered in South San Francisco, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time